Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Main Category: Parkinson's Disease Article Date: 20 Feb 2013 - 2:00 PST Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") have announced the results of the Phase II, randomised, double blind, placebo controlled, dos

Good day, ladies and gentlemen, and welcome to the BioCryst Fourth Quarter 2012 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduce your host for today, Mr. Robert Bennett

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1. The results from the ENGAGE study w

Ladies and gentlemen thank you for standing by. Welcome to The Empire District Electric Fourth Quarter 2012 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct a question-and-ans

Good day, ladies and gentlemen, and welcome to the comScore Fourth Quarter 2012 Earnings Conference Call. My name is Keith, and I'll be your operator for today. [Operator Instructions] As a reminder, today's conference is being recorded for replay purpos

Good morning, and welcome to the Realogy Holdings Corporation full-year 2012 conference call via webcast. Today’s call is being recorded and a written transcription will be available in the investor information section of the company’s website later toda